Skip to content

The anti-T2DM mechanism studies of triterpene C43 in Poria cocos mediated by odd-chain lyso-phospatidylcholine (17:0)

The anti-T2DM mechanism studies of triterpene C43 in Poria cocos mediated by odd-chain lyso-phospatidylcholine (17:0)

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056980
Enrollment
Unknown
Registered
2022-02-25
Start date
2022-03-01
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabete

Interventions

Group 1 :

Sponsors

Beijing Shijitan hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients consistent with diagnostic criteria of diabetes (fasting glucose > 6.1 mmol/L); 2. Patients consistent with diagnostic criteria of prediabetes (1. IFG: FPG 5.6-6.9 mmol/L or 2. IGT: OGTT 2h PG 7.8-11.0 mmol/L or 3. A1C 5.7-6.4%); 3. Patients aged between 20 and 80 years; 4. Patients signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with following cerebrocardiovascular event: cerebrovascular accidents, myocardial infarction or heart failure within 6 months; severe organic cardiopathy; giant or dissecting aneurysms; angina pectoris; atrioventricular block over II degree and sicksinussyndrome; 2. Patients with impaired function of liver and kidney (AST and ALT >= 1.5 times of upper limit of normal value; Cr > normal value; positive urine protein; non-menses); 3. Fasting triglyceride >= 10 mmol/L; 4. Patients with other endocrine diseases, autoimmune disorders, tumor or severe lethal diseases administered with glucocorticoid, antibiotics or Chinese herbs; 5. Women in pregnancy or to be pregnant; women in lactation; 6. Patients with psychosis or insight; patients who are unable to express exact intention or dont cooperate (dont obey the regulation of diet and medication); 7. Patients participating or participated other clinical trials within 4 weeks; 8. Allergic patients.

Design outcomes

Primary

MeasureTime frame
microbiota;

Countries

China

Contacts

Public ContactBao Li

Capital Medical University Affiliated Beijing Shijitan Hospital

libao0133@163.com+86 18301437956

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026